Industries World

Dutch Competition Regulator Investigates Biogen Over Access to MS Drug Safety Test

The ACM is examining whether Biogen restricts its Stratify blood test to patients on its Tysabri drug, which could hinder rivals such as Sandoz's biosimilar Tyruko.

Biogen headquarters in Cambridge, Massachusetts
The Philip A. Sharp Building in Cambridge, Massachusetts, which houses Biogen's headquarters. Photo: Astrophobe / Wikimedia Commons (CC BY-SA 4.0) (file)

THE HAGUE, Netherlands – The Netherlands Authority for Consumers and Markets (ACM) has opened an investigation into Biogen. The regulator is examining whether the U.S. drugmaker abused a dominant position by making a blood test available only to patients treated with its multiple sclerosis drug Tysabri.

Highlights

  • ACM is examining how Biogen supplies its anti-JCV blood test, Stratify.
  • The test is available only to patients on or considering Tysabri.
  • Italy’s competition authority opened a similar probe earlier this year.

What is being examined

Tysabri contains natalizumab, and patients taking it are at risk of a life-threatening brain infection, progressive multifocal leukoencephalopathy. That risk can be estimated with an anti-JCV blood test such as Stratify. Biogen provides the test free of charge, but only to patients on Tysabri, STAT reported.

The ACM said the practice may prevent new and existing suppliers of natalizumab-based medicines from competing effectively. That “could have consequences for prices, availability, and the freedom of choice of healthcare providers and patients,” the authority said, according to NL Times. Tyruko, a biosimilar version of Tysabri sold by Sandoz, is among the rival treatments, STAT said.

Tysabri is Biogen’s biggest-selling medicine.

Next steps

The ACM stressed that companies may hold dominant positions but must not abuse them. It said it will assess whether Biogen broke competition rules and may conclude that it did not. The regulator has invited anyone with relevant information about Tysabri or the Stratify test to file a report.

Italy’s competition authority, the AGCM, launched a similar investigation into Biogen earlier this year, and the two regulators are working together where their probes overlap, the ACM said.

A regulator focused on drug markets

The ACM lists prescription drugs as one of its key priorities. In 2021 it fined Leadiant millions of euros for charging excessive prices for a drug for a rare metabolic disorder. In 2022 Pfizer changed its rules after penalising hospitals for using cheaper alternatives to its arthritis drug Enbrel, NL Times reported.

Why it matters

The case tests whether tying a safety test to a branded drug can limit competition from biosimilars, which the ACM says could affect prices and patient choice. Regulators in two EU countries are now examining the same practice.

Sources

Filed under

Industries World

Written by

Tumisang Bogwasi

Tumisang Bogwasi, Founder & CEO of Brimco. 2X Award-Winning Entrepreneur. It all started with a popsicle stand.

More from this writer